Persistent Asset Partners Ltd Purchases Shares of 416,035 Palisade Bio, Inc. $PALI

Persistent Asset Partners Ltd purchased a new stake in Palisade Bio, Inc. (NASDAQ:PALI) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 416,035 shares of the company’s stock, valued at approximately $978,000. Persistent Asset Partners Ltd owned approximately 0.28% of Palisade Bio as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Franklin Resources Inc. bought a new stake in shares of Palisade Bio during the 4th quarter worth $11,968,000. Renaissance Technologies LLC bought a new position in shares of Palisade Bio during the fourth quarter valued at about $5,599,000. Vivo Capital LLC bought a new position in shares of Palisade Bio during the fourth quarter valued at about $5,390,000. Geode Capital Management LLC grew its stake in shares of Palisade Bio by 5,780.7% during the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after buying an additional 1,538,832 shares during the last quarter. Finally, Exome Asset Management LLC bought a new position in shares of Palisade Bio during the fourth quarter valued at about $1,782,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Trading Up 5.3%

NASDAQ:PALI opened at $1.78 on Wednesday. The company has a 50-day moving average price of $1.98 and a 200-day moving average price of $1.91. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.86. The stock has a market cap of $308.97 million, a price-to-earnings ratio of -1.76 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities analysts forecast that Palisade Bio, Inc. will post -0.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on PALI. HC Wainwright began coverage on shares of Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price on the stock. Stifel Nicolaus began coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. Wolfe Research began coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings lowered Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $10.20.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.